Skip to main content

PALVELLA THERAPEUTICS, INC.

corporate_fare Company Profile

PALVELLA THERAPEUTICS, INC.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed PVLA - Latest Insights

PVLA
Apr 07, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
PVLA
Mar 31, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
9
PVLA
Mar 31, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
PVLA
Mar 31, 2026, 7:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
PVLA
Mar 30, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
PVLA
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
PVLA
Mar 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
PVLA
Feb 26, 2026, 5:33 PM EST
Source: Unknown
Importance Score:
8
PVLA
Feb 26, 2026, 5:31 PM EST
Filing Type: 8-K
Importance Score:
8
PVLA
Feb 24, 2026, 4:27 PM EST
Filing Type: 424B5
Importance Score:
8
PVLA
Feb 24, 2026, 4:23 PM EST
Filing Type: 8-K
Importance Score:
7
PVLA
Feb 24, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
9
PVLA
Jan 29, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
PVLA
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
PVLA
Jan 02, 2026, 8:02 AM EST
Filing Type: S-3
Importance Score:
8